Cancer Immunotherapy & Immuno-monitoring: Mechanism, Treatment, Diagnosis, and Emerging Tools

In the past decade, significant progresses have taken place in the field of cancer immunotherapy. Tumor-targeting immunotherapies are being developed for most human cancers, including melanoma, prostate cancer, glioblastoma, sarcoma, lung carcinoma and hepatocellular carcinoma. The FDA has approved...

Full description

Bibliographic Details
Format: eBook
Language:English
Published: Frontiers Media SA 2014
Series:Frontiers Research Topics
Subjects:
Online Access:Open Access: DOAB, download the publication
Open Access: DOAB: description of the publication
LEADER 03463namaa2200457uu 4500
001 doab42640
003 oapen
005 20210211
006 m o d
007 cr|mn|---annan
008 210211s2014 xx |||||o ||| 0|eng d
020 |a 978-2-88919-380-6 
020 |a 9782889193806 
024 7 |a 10.3389/978-2-88919-380-6  |2 doi 
040 |a oapen  |c oapen 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
720 1 |a Chao Ma  |4 aut 
720 1 |a Antoni Ribas  |4 aut 
720 1 |a Rong Fan  |4 aut 
245 0 0 |a Cancer Immunotherapy & Immuno-monitoring: Mechanism, Treatment, Diagnosis, and Emerging Tools 
260 |b Frontiers Media SA  |c 2014 
300 |a 1 online resource (97 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Frontiers Research Topics 
506 0 |a Open Access  |f Unrestricted online access  |2 star 
520 |a In the past decade, significant progresses have taken place in the field of cancer immunotherapy. Tumor-targeting immunotherapies are being developed for most human cancers, including melanoma, prostate cancer, glioblastoma, sarcoma, lung carcinoma and hepatocellular carcinoma. The FDA has approved multiple molecular immunotherapeutics, such as Ipilimumab; cellular immunotherapies (e.g. adoptive cell transfer) are being tested in phase II/III clinical trials. Immunotherapetics has evolved into a sophisticated field: Multimodal therapeutic regimens are administrated to induce focused responses, curtail side- effects and improve therapeutic efficacy. The lack of effective clinical assessment tools remains a major challenge. Because of the intricacy of antitumor response, it is essential to scrutinize individual tumor-targeting immune cells and their functions at the finest details - molecules. In this regard, flow cytometry analysis modernized hematology and allows characterization of surface molecular signature on individual cells. More recently, microchip technologies and new variations of cytometry have enormously expanded the spectrum, throughout and multiplexity of single cell analysis. Nowadays, tens of millions of readouts can be generated through the course of a cancer immunotherapy to monitor the abundance, phenotype and a myriad of effector functions of single immune cells. At the same time, big data analytics and data mining methodologies have been adapted to achieve sensible diagnostic interpretations. Such a marriage of technology and analytics opens the door for informative point-of-care assessment of therapeutic efficacy and ensures timely therapeutic decisions. The new generation of personalized clinical diagnostics will revolutionize healthcare in the years to come. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |u https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a cancer immunotherapy 
653 |a immune assessment 
653 |a immune suppression 
653 |a single cell analysis 
653 |a tumor immunity 
793 0 |a DOAB Library. 
856 4 0 |u http://journal.frontiersin.org/researchtopic/834/cancer-immunotherapy-immuno-monitoring-mechanism-treatment-diagnosis-and-emerging-tools  |7 0  |z Open Access: DOAB, download the publication 
856 4 0 |u https://directory.doabooks.org/handle/20.500.12854/42640  |7 0  |z Open Access: DOAB: description of the publication